Latest news with #STARR
Globe and Mail
18 hours ago
- Business
- Globe and Mail
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on X (formerly Twitter) and LinkedIn.
Business Wire
19 hours ago
- Business
- Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2025 after the market close on Monday, August 11 and will also host a conference call and webcast at 4:30 pm Eastern Time on August 11, 2025. Arcturus Therapeutics Second Quarter 2025 Earnings Conference Call Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on X (formerly Twitter) and LinkedIn.
Fox News
05-06-2025
- Business
- Fox News
DC restaurant groups blast Dems' 'baseless' boycott threat reportedly backed by AOC, Sanders
"Dozens" of Democratic lawmakers are boycotting six high-dollar Washington, D.C., restaurants over labor disputes with two restaurant groups, according to Axios. One of those restaurant groups, STARR, told Fox News Digital the boycott push was "baseless." "To the best of our knowledge, a majority of Le Diplomate employees have no interest in engaging in that process nor in being represented by a union," a STARR representative said. "A boycott of any kind can result in lost hours, wages, and tips that our hardworking employees rely upon. It is unfortunate that an organization that claims to want to represent the employees of Le Diplomate would call for an action that would harm them." The owner of the second business, Knightsbridge Restaurant Group, took a shot at the lawmakers more directly. "How many of these congress members even know themselves that they're signing?" he told Axios. STARR owns Osteria Mozza, The Occidental and Le Diplomate – the latter of which has been a mainstay among the Washington, D.C., elite for years, including former Presidents Barack Obama and Joe Biden. Knightsbridge owns Rasika, Modena and Bombay Club. Knightsbridge did not respond to a request for comment by Fox News Digital. Obama was spotted at Osteria Mozza with Amazon founder Jeff Bezos earlier this year, CBS News reported. The boycott is being run by Local 25, a hospitality workers' union. "Hundreds of workers at some of D.C.'s most prominent and lucrative restaurants – including Le Diplomate and Rasika – have been organizing to join UNITE HERE Local 25. These workers have endured months of union busting from their employers – STARR Restaurants and Knightsbridge Restaurant Group," a flyer on the boycott obtained by Axios read. "D.C. Restaurant workers have been holding informational picket lines outside STARR and Knightsbridge Restaurants, including STARR's Osteria Mozza, The Occidental and Le Diplomate, and Knightsbridge's Rasika, Modena and Bombay Club. Now, workers are calling for D.C. customers to boycott these restaurants, asking the public not to eat, meet or drink at these locations." Reps. Alexandria Ocasio-Cortez, D-N.Y., Nancy Pelosi, D-Calif., and Sen. Bernie Sanders, I-Vt., are reportedly among the signatories. Fox News Digital reached out for comment.
Yahoo
16-05-2025
- Business
- Yahoo
STAAR Surgical plans $30m share buyback despite China market woes
Shares in STAAR Surgical jumped today (16 May) after the implantable lens developer revealed plans to bring $30m worth of shares back under ownership, a positive sign for the company despite revenue struggles due to weak demand in China. US-based STAAR, whose board authorised the share repurchase programme of outstanding common stock today, said the timing, manner, and price of any transactions will be determined at its discretion. STAAR had approximately 49.5 million shares of common stock outstanding as of March 2025. Shares in the Nasdaq-listed company rose 5% to a price of $19.25 at market open on 16 May following the announcement. STAAR has a market cap of $906m. STAAR may buy back share in the open market, through privately negotiated transactions, or by entering structured repurchase agreements with third parties. Block purchases, which involve buying a large number of shares to avoid market price fluctuations, could also be an avenue. STARR said that routes are alongside or under Rule 10b5-1 trading plans – a regulation that allows company insiders to trade stock without violating trading laws. STAAR stated it may modify or suspend the programme at any time, though it currently plans to continue it over the next six months. Buying back stock is a way for companies with auxiliary cash to boost earnings per share. It also increases the value of remaining shares and adjusts voting rights. However, the size and nature of buybacks depend on how much the company has in reserve. STAAR stated that the share repurchase will be funded from cash on hand and cash generated from operations. The company had $222.8m to call upon as of March 2025. Buying back shares has become a popular trend in 2025 as companies look to shore up ownership stakes amid an uncertain macroeconomic climate. In the pharmaceutical industry, Sanofi is executing a $5.1bn share buyback programme in 2025. 'Our decision to initiate a share repurchase programme underscores the boards and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth,' said STAAR Surgical's CEO Stephen C Farrell. STAAR struggled with revenue in 2024, posting just $49m in full-year results – a drop from $76.3m in 2023. During its 2024 earnings report, the company blamed the 'significant decline in China revenue' amid government initiatives affecting device procurement. It is an issue affecting a broad cohort of players in the medtech industry. Philips, for example, continues to expect a subdued demand for products in the region this year. STAAR's product line is called EVO, with various brands for myopia, astigmatism, and hyperopia. The devices are implantable collamer lenses (ICLs) that are administered during surgical procedures and offer long-term correction to vision. Although more expensive, ICLs – which are reversible – offer an alternative to laser-assisted approaches for those unsuitable for laser surgery or for those who do not want to have permanent changes to their eye. The global intraocular lens device market is forecast to grow to $5.6bn by 2034, up from $4.5bn in 2024, according to analysis by GlobalData. STAAR is estimated to occupy 1.8% of the global market share. "STAAR Surgical plans $30m share buyback despite China market woes" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
16-05-2025
- Business
- Yahoo
STAAR Surgical plans $30m share buyback despite China market woes
Shares in STAAR Surgical jumped today (16 May) after the implantable lens developer revealed plans to bring $30m worth of shares back under ownership, a positive sign for the company despite revenue struggles due to weak demand in China. US-based STAAR, whose board authorised the share repurchase programme of outstanding common stock today, said the timing, manner, and price of any transactions will be determined at its discretion. STAAR had approximately 49.5 million shares of common stock outstanding as of March 2025. Shares in the Nasdaq-listed company rose 5% to a price of $19.25 at market open on 16 May following the announcement. STAAR has a market cap of $906m. STAAR may buy back share in the open market, through privately negotiated transactions, or by entering structured repurchase agreements with third parties. Block purchases, which involve buying a large number of shares to avoid market price fluctuations, could also be an avenue. STARR said that routes are alongside or under Rule 10b5-1 trading plans – a regulation that allows company insiders to trade stock without violating trading laws. STAAR stated it may modify or suspend the programme at any time, though it currently plans to continue it over the next six months. Buying back stock is a way for companies with auxiliary cash to boost earnings per share. It also increases the value of remaining shares and adjusts voting rights. However, the size and nature of buybacks depend on how much the company has in reserve. STAAR stated that the share repurchase will be funded from cash on hand and cash generated from operations. The company had $222.8m to call upon as of March 2025. Buying back shares has become a popular trend in 2025 as companies look to shore up ownership stakes amid an uncertain macroeconomic climate. In the pharmaceutical industry, Sanofi is executing a $5.1bn share buyback programme in 2025. 'Our decision to initiate a share repurchase programme underscores the boards and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth,' said STAAR Surgical's CEO Stephen C Farrell. STAAR struggled with revenue in 2024, posting just $49m in full-year results – a drop from $76.3m in 2023. During its 2024 earnings report, the company blamed the 'significant decline in China revenue' amid government initiatives affecting device procurement. It is an issue affecting a broad cohort of players in the medtech industry. Philips, for example, continues to expect a subdued demand for products in the region this year. STAAR's product line is called EVO, with various brands for myopia, astigmatism, and hyperopia. The devices are implantable collamer lenses (ICLs) that are administered during surgical procedures and offer long-term correction to vision. Although more expensive, ICLs – which are reversible – offer an alternative to laser-assisted approaches for those unsuitable for laser surgery or for those who do not want to have permanent changes to their eye. The global intraocular lens device market is forecast to grow to $5.6bn by 2034, up from $4.5bn in 2024, according to analysis by GlobalData. STAAR is estimated to occupy 1.8% of the global market share. "STAAR Surgical plans $30m share buyback despite China market woes" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
